MedTrace Logo

Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

NCT02237703 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2017-01-20

No results posted yet for this study

Summary

This study uses positron emission tomography (PET) imaging to measure kappa opioid receptors (KOR) in the brains of individuals with and without post-traumatic stress disorder (PTSD). The investigators propose to recruit 45 drug-naïve individuals, N=15 patients with PTSD, N=15 trauma-exposed, but asymptomatic healthy control subjects (TC) and N=15 non-trauma exposed healthy control subjects (HC) to participate in one magnetic resonance imaging (MRI) and one PET study. The investigators will also carefully document trauma history, and collect behavioral and neuroendocrine measures to provide a more integrative view on the neurobiology of PTSD and its phenotype. The investigators predict PTSD will show greater carbon - 11 (11C)\[11C\]LY2795050 volume of distribution (VT) (i.e. KOR binding) values than control populations in an a priori defined PTSD circuit.

Conditions

  • Post-traumatic Stress Disorder (PTSD)
  • Trauma

Interventions

OTHER

Positron emission tomography (PET) imaging

Positron emission tomography (PET) imaging

Sponsors & Collaborators

Principal Investigators

  • Charles Marmar, MD · NYU School of Medicine

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-03-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237703 on ClinicalTrials.gov